ClinicalTrials.gg
Status unknownNCT04883996Updated May 13, 2021

A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia

A Phase 1/2 interventional study of 1% EXP039 and Saline control in Hyperopia and Myopia, sponsored by Canyon City Eyecare. Status unknown at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Canyon City Eyecare · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2020, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Hyperopia with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Hyperopia · United States.

Planned enrollment
28th of 54
60 · median 61
Started
2020
with 3 others
Phase 1/2
4 of 68
none open now
Registered
49th of 68
by date

Among the 68 studies in Hyperopia with a site in United States, this one is the 28th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2020, is one of 4 in phase 1/2, and was the 49th registered.

Hyperopia

156 studies on the registry are indexed under Hyperopia; 20 are open to participants now.

Browse Hyperopia studies →

Open to participants now

3 of the 68 studies in Hyperopia with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hyperopia studies recruiting now, 3 (30%) set no upper age limit and 7 (70%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Hyperopia with a site in United States, or all of them as a file.
02

Study summary

Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in Participants with Myopia or Hyperopia

Read the detailed description

To characterize the effect of pupillary miosis as achieved with EXP039 1% ophthalmic solution in terms of mean number of lines (Early Treatment Diabetic Retinopathy Study [ETDRS]) of improvement from baseline in binocular (both eyes open) mesopic high-contrast uncorrected distance visual acuity (UDVA) at 1-hour post treatment.

03

Conditions studied

  • Hyperopia
  • Myopia

Browse trials for

Keywords

  • Hyperopia
  • Myopia
  • Visual Acuity
  • Mesopic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 to ≤80 years
  2. Participants must be in good general health, with no significant medical problems that, in the opinion of the investigator, would preclude participation in the trial, at Screening and/or before administration of the dose of study drug
  3. Low-to-moderate hyperopia (SER of +0.50D to +2.00D) or myopia (SER of -0.50 D to -4.00D) at Screening
  4. Between-eye SER difference of no more than 0.50D
  5. Best-corrected distance visual acuity better than or equal to 20/20 in both eyes at Screening
  6. Astigmatism in each eye of less than or equal to 0.75D with manifest refraction at Screening
  7. Women of (WOCBP) must have a negative urine pregnancy test at Screening
  8. WOCBP must be non-pregnant and non-lactating, and must use a medically approved, highly effective method from Screening until study completion, including the follow up period. Female participants who are in same sex relationships are not required to use contraception.Males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a WOCBP, the participant and his partner must use a medically approved, highly effective contraceptive method from Screening until study completion, including the follow-up period.
  9. Males must not donate sperm for at least 90 days after the last dose of study drug
  10. Participants must have the ability and willingness to attend the necessary visits
  11. Participants must be willing and able to provide written after the nature of the study has been explained and prior to the commencement of any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any central corneal abnormality (e.g., keratoconus, Pellucid marginal degeneration, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that is likely to interfere with visual acuity
  2. Moderate or severe dry eye as defined by corneal fluorescein staining score of ≥3 on Oxford scale at Screening
  3. Any pupillary or iris abnormality (e.g., anisocoria of >1 mm between eyes at Screening or baseline, abnormal pupil shape in either eye, iris transillumination defects, or any congenital or traumatic defect of the iris)
  4. Narrow iridocorneal angles (Shaffer grade ≤2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy
  5. Intraocular pressure (IOP) \<8 mmHg or >23 mmHg in either eye or history of glaucoma or ocular hypertension
  6. Any clinically significant abnormal lens finding (e.g., cataract, loose zonules, exfoliation, pseudoexfoliation)
  7. History of any intraocular surgery including cataract surgery or phakic intraocular lens surgery
  8. History in either eye of previous corneal inlay, full- or partial-thickness corneal transplant, radial keratotomy or any corneal surgery including laser-based corneal refractive surgery
  9. Any clinically significant abnormal finding on dilated fundus examination in either eye or known history of retinal detachment, retinal trauma, retinal or vitreal surgery, or clinically significant retinal disease in either eye
  10. Clinically significant strabismus or diplopia
  11. History of stereo vision difficulties
  12. History of optic neuropathy or amblyopia in either eye
  13. Use of orthokeratology contact lenses within the past 1 month prior to EXP039 dosing on Day 1
  14. Use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes
  15. Planned use of any contact lenses during the study
  16. Allergy to pilocarpine or any of its
  17. Serious systemic illness that, in the opinion of the Investigator's, would render the participant ineligible
  18. Pre-planned hospitalization or ocular or systemic surgery during the study period
  19. History of any substance abuse (alcohol and/or illegal drugs) and not willing to abstain from drug(s) and reasonably limit alcohol consumption to approximately 2 alcoholic beverages per day during the 30-day study period
  20. Participation in any other study of therapy during the study period or within the last 30 days or 5 half-lives, whichever is longer
  21. Unwilling or unable to complete study procedures or to be followed up for the duration of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    EXP039

    At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.

    Drug: 1% EXP039

  • Placebo comparator
    Saline control

    At Visit 1, single dose 1 drop of saline is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop EXP039 1% at Visit 2.

    Other: Saline control

Interventions

06

What researchers measure

Primary outcomes

  1. UDVA

    Mesopic high-contrast uncorrected distance visual acuity

    Time frame: 1 hour

07

Study locations

1 site
  • Canyon City Eyecare
    Azusa, California 91702, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2020 (actual). Primary completion is estimated for Jul 2021, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 12, 2021
StartActual
Dec 1, 2020
Primary completionEst.
Jul 31, 2021
CompletionEst.
Aug 30, 2021
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04883996
Lead sponsor
Canyon City Eyecare
Collaborators
Nevakar, Inc.
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Dec 1, 2020
Primary completion
Jul 31, 2021 (estimated)
Completion
Aug 30, 2021 (estimated)
Last update
May 13, 2021

Study contacts

Milton Hom, OD FAAO
principal investigator · Canyon City Eyecare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prizloncabtagene autoleucel

Start the discussion